←Back to Expert Scholars
Translational Medicine / 转化医学Liquid Biopsy, CAPP-Seq and Methylation
Maximilian Diehn
MD, PhD
🏢Stanford University🌐USA
Professor of Radiation Oncology
85
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Maximilian Diehn co-developed CAPP-Seq, one of the most widely used targeted ctDNA platforms, and extended it with methylation and fragmentomic features. His work defines MRD and early detection in lung and other cancers. He leads a translational liquid biopsy lab at Stanford.
Share:
🧪Research Fields 研究领域
CAPP-Seq
ctDNA
methylation
minimal residual disease
lung cancer
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Maximilian Diehn 的研究动态
Follow Maximilian Diehn's research updates
留下邮箱，当我们发布与 Maximilian Diehn（Stanford University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment